CITIUS ONCOLOGY, INC. Operating Income Loss

Quick Answer

CITIUS ONCOLOGY, INC. reported Operating Income Loss of -$23.52 million for the year ending 2025.

  • CITIUS ONCOLOGY, INC. showed a decrease of -14.3% in Operating Income Loss from 2024 to 2025.
  • This data is from CITIUS ONCOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), CITIUS ONCOLOGY, INC.'s Operating Income Loss has declined by 16,931.3%.
  • Historical annual values: Fiscal year 2025: -$23.52 million | Fiscal year 2024: -$20.57 million | Fiscal year 2023: -$1.01 million | Fiscal year 2022: -$138.1 thousand.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: